Chanice Henry | 09/08/2015
NHS England has reviewed the arrangement of its Cancer Drug Fund and has announced the de-listing of some life-extending cancer treatments.
In a recent announcement NHS England noted that the decision to re-evaluate the treatments listed on the Cancer Drug Fund (CDF) fruited after projections highlighted that unless further prioritisation was employed spending was on track to rise to £410 million - which would have been £70 million over budget.
The move has met concern...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma 2026 | AI Commercial, Medical & Patient Care
September 9 - 10, 2026
Berlin, Germany
Register Now |
View Agenda |
Learn More
Pharmaceutical Launch Excellence Summit US
September 30 - October 1 2026
Hyatt Regency Boston Harbor, Boston, US
Register Now |
View Agenda |
Learn More